Medtainer, Inc. Completes Acquisition of Advanced Container Technologies

October 20, 2020

On October 9, 2020, Medtainer, Inc. consummated an exchange agreement with California-based Advanced Container Technologies, Inc. and its shareholders under which these shareholders exchanged their shares in ACT for 50,000,000 shares of Medtainer’s common stock. As a result, ACT has become the wholly-owned subsidiary of Medtainer.

In connection with this transaction, Medtainer, which is a Florida corporation, changed its name to Advanced Container Technologies, Inc., effective October 3, 2020, and its trading symbol to ACTX, effective 20 business days after October 9. On October 8, 2020, the outstanding shares of Medtainer’s common stock were reverse-split on the basis of one new share for every 59 shares outstanding. Medtainer now has 51,001,860 shares outstanding, which are held by 427 shareholders.

On August 6, 2020, ACT and GP Solutions, Inc. (“GP”), of Colton, California, entered into a Distributorship Agreement, under which ACT has the exclusive right to market, sell and distribute GP’s products in the United States and its territories. This agreement has an initial term that expires on December 31, 2025, and is renewable indefinitely as long as ACT meets prescribed sales targets. GP manufactures fully insulated, food-grade shipping containers that are specifically modified to provide an optimal controlled environment for growing a wide range of horticultural and agricultural products in all environments and climates. The containers can be used to grow large amounts products in a small volume and in a short period: for example, according to GP, 4,000 heads of romaine lettuce can be grown in a single container in less than 5 weeks.

Medtainer entered into the exchange agreement because its board of directors believed that the company needed to expand its product base and become profitable. Douglas P. Heldoorn, the chief executive officer of Medtainer and a member of its board of directors, stated: “Our sales have been relatively flat for the past several years and the Company has a history of losses. We are delighted to have acquired ACT and believe that it offers an opportunity to expand our products, enter into a new market and increase shareholder value.”

On October 9, Daniel Salinas, of Broken Arrow Oklahoma and Eric Horton, of San Diego California, were appointed to the board of directors, following the resignations of Russell Ward and Jeffory A. Carlson, and Mr. Carlson was appointed chief financial officer of Medtainer.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”